Stocks and Investing Stocks and Investing
Thu, February 15, 2024

Andy Chen Initiated (VRTX) at Buy on, Feb 15th, 2024


Published on 2024-10-28 08:58:45 - WOPRAI, Andy Chen
  Print publication without navigation


Andy Chen of Wolfe Research, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy on, Feb 15th, 2024.

Andy has made no other calls on VRTX in the last 4 months.



There are 16 other peers that have a rating on VRTX. Out of the 16 peers that are also analyzing VRTX, 6 agree with Andy's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Liisa Bayko of "Evercore ISI Group" Downgraded from Buy to Hold and Increased Target to $438 on, Tuesday, February 6th, 2024
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $420 on, Tuesday, February 6th, 2024
  • William Pickering of "Bernstein" Downgraded from Buy to Hold on, Friday, February 2nd, 2024
  • Naz Rahman of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, January 31st, 2024
  • Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023


These are the ratings of the 10 analyists that currently disagree with Andy


  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $472 on, Tuesday, February 6th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $450 on, Tuesday, February 6th, 2024
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $457 on, Tuesday, February 6th, 2024
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $540 on, Tuesday, February 6th, 2024
  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $440 on, Tuesday, February 6th, 2024
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $508 on, Wednesday, January 31st, 2024
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $559 on, Wednesday, January 31st, 2024
  • Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
  • Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
  • Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023
Contributing Sources